1. Haemodynamic responses to exercise, posture and nitrates were measured before and after 8 weeks of therapy with an arteriolar smooth muscle specific calcium antagonist, nicardipine, in eight patients with congestive heart failure (New York Heart Association class I1 or Ill).
INTRODUCTION
Patients with congestive heart failure invariably have an elevated systemic vascular resistance when compared with normal subjects; in mild heart failure this may be evident only on exertion, while in severe heart failure it is a characteristic at rest and further impairs cardiac function. Reduction in left ventricular afterload, the main static component of which is systemic vascular resistance, is beneficial in patients with heart failure [l]. This benefit may be manifest as an improvement in symptoms at rest in severe heart failure and as clinical and haemodynamic improvement on exercise and, perhaps, at rest in those less compromised. Certain vasodilators [2] or a combination of vasodilators [ 31 appear, in addition, to improve prognosis, although factors other than their direct vasodilator action may be responsible for this effect [4]. Tolerance to some vasodilators has been reported [5, 61, while for others its existence is controversial [7, 8] ; nevertheless it is an important determinant in the choice of vasodilator employed. Little is known about the effect of treating heart failure on arteriolar responses to various physiological and pharmacological stimuli: even in the absence of significant resting vasodilatation there may be increased responsiveness to other stimuli which may contribute to the clinical benefit of the drug in heart failure.
In order to investigate possible modification of vascular responses after chronic heart failure therapy, we measured haemodynamic responses to exercise, posture and sublingual glyceryl trinitrate (GTN) before and after 8 weeks of treatment with nicardipine, a calcium antagonist without direct cardiac effects in therapeutic dosage [9-131. Chronic responses were measured at least 10 h after the last dose of the drug when any residual resting effects would be minimal or absent. The acute haemodynamic responses to an intravenous infusion of nicardipine were also measured both before and after chronic therapy in order to assess possible attenuation following chronic dosing.
METHODS

Patients
Ten male patients aged 39-7 1 years (mean 58.9 years) were recruited to the study. Their clinical details are given in Table 1 . All had chronic congestive heart failure of at least 3 months duration; eight were New York Heart Association (NYHA) classes I1 and Ill and two were NYHA class IV. Nine had ischaemic heart disease and one had dilated cardiomyopathy. One patient was in stable atrial fibrillation. All were receiving diuretics, up to 80 mg of frusemide and 10 mg of amiloride daily, and seven were receiving digoxin. These drugs were continued unchanged throughout the study. Two patients had received isosorbide dinitrate until 2 weeks before the study but no other vasodilators had been given. All patients gave written informed consent for the study, which had been approved by the Hospital Ethics Committee.
Study protocol
The study was of 8 weeks duration and of open design. Nine patients underwent treadmill exercise using a modified Bruce Protocol (3 min stages of 0, 5 and 10% gradient at 1.7 m.p.h., 12% gradient at 2.5 m.p.h. and 14% gradient at 3.4 m.p.h.). One patient, no. 3, had a mild hemiparesis and was unable to exercise. All patients underwent training for both treadmill and bicycle exercise on at least two occasions during the week before the study until consecutive exercise durations were within 5% of each other. All tests were performed to a maximal symptomlimited exercise and were undertaken 2-3 h after medication.
After 24 h bed-rest and 2 h after medication, a thermodilution Swan-Ganz catheter was inserted under local anaesthesia into the left subclavian vein and advanced into the pulmonary circulation for measurement of pulmonary pressures and cardiac output. Heart rate was taken from a simultaneous electrocardiogram and systemic arterial pressure was measured from the right arm using a sphygmomanometer: the diastolic pressure was taken at Korotkoff phase V and the mean arterial pressure was calculated as diastolic pressure plus onethird (systolic pressure minus diastolic pressure).
After catheter insertion a period of at least 1 h was allowed for stabilization. Measurements were then recorded supine and after 5 min erect both before and after GTN (0.5 mg sublingually). A further period of 30 min was allowed for parameters to return to the pre-GTN Table 1 . Clinical details of the 10 patients studied Abbreviations: SR, sinus rhythm; AF, atrial fibrillation; IHD, ischaemic heart disease; DCM, dilated cardiomyopathy; HCT, hydrochlorothiazide. NY HA classification: I, no limitation of physical activity; 11, slight limitation of physical activity, comfortable at rest; 111, marked limitation of physical activity, comfortable at rest; IV, unable to carry out any physical activity, symptoms may be present at rest. min until maximal symptom-limited exercise was attained when further recordings were made. The patient then underwent a further period of bed-rest and the next morning haemodynamic measurements were repeated supine and after 5 min standing before and after nicardipine (10 mg intravenously over 10 min). All recordings were complete 10 min after the full dose. The catheter was then removed and nicardipine (20 mg, three times daily) was commenced. Regular observations were made as an out patient and, after 8 weeks oral therapy, the patient was re-admitted and the above protocol repeated. During week 8 all recordings were made at least 10 h after the last oral dose of nicardipine.
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Statistical analysis
were made within groups by using Student's paired t-test.
Results are expressed as means f SEM, and comparisons
RESULTS
Two patients, both NYHA class IV, were withdrawn from the study..Patient no. 2 was withdrawn after 2 weeks because of further deterioration and patient no. 7 was withdrawn after 1 week because of a pulmonary embolism (he had not taken medication for 4 days before withdrawal). Statistical analysis was carried out on the data from the remaining eight patients.
All eight patients of NYHA classes I1 and Ill improved by one functional class during the study. Cardiothoracic ratios from the chest radiographs were unchanged over the 8 week period (0.51 f O . l vs 0.52*0.01, NS). Nicardipine was well tolerated and no side-effects were reported.
Acute and chronic haemodynamic effects at rest
There was no significant difference in resting control haemodynamic parameters on days 1 and 2 of the protocol either at week 0 or at week 8 (Tables 2 and 3 ). All control haemodynamic measurements during week 8 were obtained at least 10 h after the last oral dose o f nicardipine. Interestingly, systemic vascular resistance and mean arterial pressure on day 2 of the study (Table 2) were significantly lower than the corresponding values obtained during week 0. Thus, supine and erect systemic vascular resistances were, respectively, 2 12 f 17 kPa I -' s (21225166 dyn s cm-s) and 2 3 9 f 1 5 kPa I -' s (2391 f 152 dyn s cm-s) during week 0 compared with 178 k 13 kPa I -' s (1779 f 130 dyn s cm--') and 203 k 13 kPa I -' s (2028f 128 dyn s crn-') at week 8 (P<0.05 in each case). Some residual effect on cardiac output and Table 2 . Effects of nicardipine (10 mg intravenously) on supine erect resting haemodynamic parameters at week 0 (before oral nicardipine) and at week 8 (after oral nicardipine, 20 mg three times daily) Control parameters at week 8 were measured at least 10 h after the dose. Values are means (SEM). Statistical significance of changes after intravenous nicardipine with respect to control: *P< 0.05; **P< 0.01, ***P< 0.001. Statistical significance of changes after oral nicardipine with respect to control at week 0: tP< 0.05, ttP< 0.01. Abbreviations: HR, heart rate; MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure; MPWP, mean pulmonary capillary wedge pressure; CO, cardiac output; SV, stroke volume; SVR, total systemic vascular resistance; PVR, total pulmonary vascular resistance. (17) 63 (15) 17 ( 95 (5) 23 (4) 92 (6) 13 (4) (10) 67 (18) 192 ( 14) 34 ( 10)' 2 14 ( 20) 76 ( 22) 185 (13) 45 (13)* 222 (18) 54 (11) 2 14( 14) 32( 9)* 257 (24) 60 (17) 193(21)*t 39 (8) stroke volume were similarly observed. However, on day 1 of the study (Table 3) . similar values for all parameters were observed at both week 0 and week 8 (see the Discussion). Intravenous nicardipine significantly reduced systemic vascular resistance and mean arterial pressure and increased cardiac output and stroke volume when given at week 0 and week 8. The response to intravenous nicardipine was consistently greater during week 0: systemic vascular resistance was reduced by 44%) (supine) and 39% (erect) at week 0 compared with 29% (supine) and 27"/0 (erect) at week 8. Although the acute response was less at week 8, this probably reflected a lower level of resting systemic vascular resistance so that values after acute intravenous nicardipine were quite similar, i.e. supine 1 1 8 + 4 kPa I -' s ( 1 176 f41 dyn s cm-S) at week 0 compared with 127 f 12 kPa I -' s ( 127 1 f 122 dyn s cm-') at week 8, and standing 145 +_ 7 kPa I -s (1447 f 68 dyn s cm-5) at week 0 compared with 1 4 8 f 12 kPa I -' s ( 1480 f 118 dyn s cm-5) at week 8. A similar pattern emerged for mean arterial pressure, cardiac output and stroke volume ( Table 2) .
Effect of chronic treatment on exercise
The effect of chronic vasodilator therapy on exercise tolerance varied depending on the type of exercise employed. Treadmill exercise capacity was significantly improved after 8 weeks of therapy (9.3 f 1.6 min vs 6.9 f 1.5 min, I'<0.05); in contrast, cycling duration was unaltered (8.8 f 1.2 min vs 8.5 f 1.5 min). Both forms of exercise were symptom-limited but by different symptoms. While treadmill exercise was limited by dyspnoea in all patients, bicycle exercise was limited by leg fatigue in six of the seven patients (the other developed general fatigue associated with dyspnoea). Although bicycle exercise was not prolonged after chronic therapy, haemodynamic changes observed at peak exercise were altered (Fig. 1) . Since patients exercised for similar periods at week 0 and week 8, this comparison was made at the same peak workload. After chronic therapy exercise induced significantly greater changes in cardiac output ( + 5.0 f 1 .0 I/min vs + 2.8 f 1.0 I/min, P< 0.05) and total systemic vascular rcsistancc [ -9 1 f 8 kPa I -' s ( -9 0 7 f 7 9 dyn s cm-') vs -6 4 f 1 3 kPa I -l s (-639f 128 dyn s cm), I'<O.OSI. In contrast, the responses of heart rate and mean arterial pressure were similar on exercise after 8 weeks [ + 4 1 f 8 beats/min vs + 33 f 6 beats/min and + 8 f 4 mmHg ( + 1.07 f 0.53 kPa) vs + 6 f 7 mmHg ( + 0.80 f 0 . Y 3 kPa), respectively\.
Thus, chronic treatment with nicardipine prolonged symptom-limited exercise capacity o n treadmill testing and produced an improved haemodynamic response to bicycle exercise. Fig. 1 . Individual changes in haemodynamic parameters to maximal symptom-limited bicycle exercise at the same workload before and after 8 weeks of therapy with nicardipine. Mean values are also given ( 0 ) . Statistical significance of changes at week 8 compared with week 0: *P<0.05. Abbreviations: HR, heart rate; MAP, mean arterial pressure; CO, cardiac output; SV, stroke volume; MPAP, mean pulmonary arterial pressure; MPWP, mean pulmonary wedge pressure; SVR, total systemic vascular resistance; PVR, total pulmonary vascular resistance. To convert mmHg to kPa, divide by 7.5.
Effect of chronic treatment on haemodynamic responses to GTN
Supine and erect haemodynamic responses to GTN (0.5 mg sublingually) are given in Table 3 and changes in degree of response are presented in Fig. 2 . Patient 3 developed dizziness after GTN while lying at week 0 and was unable to stand; a further challenge was not undertaken at week 8. Statistical analysis was therefore performed on the data from seven patients. Sublingual GTN reduced total pulmonary vascular resistance, mean pulmonary artery pressure and pulmonary capillary wedge pressure at week 0 and week 8. The responses were broadly similar, although an apparent reduction in the response was observed at week 8. Thus, GTN reduced supine and erect total pulmonary vascular resistance by 50% and 42%, respectively, at week 0 compared with 41% and 35% at week 8 (see Table 3 ). Mean pulmonary artery pressure and pulmonary capillary wedge pressure responded in a similar way, but the difference in responses at week 0 and week 8 were not statistically significant. In contrast to the decrease in effect of GTN on the pulmonary vasculature after 8 weeks of chronic therapy with nicardipine, there was an increase in its effect on the systemic vasculature. Thus, GTN caused a significantly greater reduction in erect mean arterial pressure and total systemic vascular resistance at week 8 ( -15% and -25%, respectively) compared with week 0 ( -3% and -3%) ( P < 0.05 in each case) and in supine mean arterial pressure at week 8 (-6%) compared with week 0 ( + 2%) ( P < 0.05, Fig. 2 ). Although at week 8 on day 2 control values for mean arterial pressure and systemic vascular resistance were slightly higher than corresponding values at week 0, the values after GTN at week 8 were nevertheless lower than those values at week 0, such that the magnitude of reduction was significantly greater (Table 3) .
DISCUSS I 0 N
These findings indicate that chronic treatment with the arteriolar vasodilator nicardipine produced clinical improvement as evidenced by a reduction in NY HA class in all patients and increased exercise capacity on treadmill testing. After 8 weeks of chronic treatment [here was marked improvement in the haemodynamic chimges at peak bicycle exercise at the same workload. In particular, exercise induced a 50% fall in systemic vascular resistance after 8 weeks of. treatment compared with a 37% fall initially. This ability to reduce systemic vascular resistance on exercise is perhaps the best explanation for the observed clinical improvement. It is of interest that this should occur when resting haemodynamic parameters, measured at least 10 h after the last dose of nicardipine, indicated little if any residual drug effect and therefore suggests that the improved response to exercise may not be attributable to a direct action of the drug. The increased arteriolar sensitivity to GTN further suggests that a general alteration in arteriolar function Fig. 2 . Changes in haemodynamic parameters after GTN at week 0 (before oral nicardipine, 0 ) and at week 8 (after oral nicardipine 20 mg three times daily, N), both supine (S) and erect (E). Values are means+sEM. Statistical significance of changes with respect to control: *P< 0.05. Abbreviations: CO, cardiac output; MAP, mean arterial pressure; MPWP, mean pulmonary wedge pressure; SVR, total systemic vascular resistance. To convert mmHg to kPa, divide by 7.5. accompanied chronic treatment with nicardipine. Thus, although there was little evidence of a resting arteriolar vasodilator response 10 h after nicardipine at week 8, systemic responses to exercise and GTN were increased. The present results indicate that, in addition to its direct vasodilating effect, nicardipine produced an indirect effect on general arteriolar responsiveness which is likely to have contributed to the observed clinical improvement. The general response to GTN observed here is similar to that seen in previous studies 1141, although we are unaware of any other comparative assessments before and after the treatment of heart failure. Unlike haemodynamic responses to exercise and GTN which changed after chronic treatment with nicardipine, the effect of Dosture was unaltered. This mav reflect a lesser stimulus difference in the directional change, i.e. standing increases systemic vascular resistance unlike exercise or GTN.
Calcium antagonists are not commonly used in the treatment of heart failure. Their potential negative inotropic effect and reports of clinical deterioration after their introduction [15, 161 have made them less popular than other forms of vasodilator. Recently, however, dihydropyridines have been introduced which lack significant myocardial effects. Felodipine, for example, has been reported to improve resting and exercise haemodynamic responses in heart failure with maintenance of its effects over at least a 4 week period [ 171. Nicardipine, similarly, lacks significant myocardial effects in vitro [9] and in patients with ischaemic heart disease [ 181 and has been shown to be effective in reducing afterload in hypertension and ischaemic heart*disease [lo, 131. In this study it was used primarily to examine changes in haemodynamic responsiveness during an 8 week period. Although ten patients were enrolled in the study, two patients failed to complete the 8 week period. Both were of NYHA class IV; one developed a pulmonary embolism but had, in any case, failed to comply with the study for 4 days, while the other developed progressive heart failure requiring intensive therapy. In the latter case nicardipine may have been responsible for the deterioration, although it is likely that the progression was due to the natural history of the condition. All eight patients whose data were analysed were in mild to moderate heart failure with elevated supine pulmonary wedge pressures, although erect values were within normal limits. Calcium antagonists mainly affect the systemic arterioles [ 191 and the observed haemodynamic changes in this study support this; little or no change in pulmonary pressures were observed after acute treatment. A reflex tachycardia after nicardipine was not observed, although it has been reported in other studies using similar dosages [ 10, 121. Its absence in the present study may reflect baroreflex ,dysfunction known to occur in heart failure.
The discrepancy in the control values on days 1 and 2 after 8 weeks of chronic therapy with nicardipine may have been related to different conditions on the 2 days. Although measurements were performed at least 10 h after the previous dose of nicardipine on both days, the period was slightly longer on day 1 ( 12-13 h) than on day 2 (10-1 1 h). On day 1 Swan-Ganz catheterization was performed and although 1-2 h was allowed for stabilization (i.e. consecutive control readings 15 min apart differed by <5%), the procedure may have adversely influenced the control values on day 1. tending to negate any apparent residual beneficial effect of nicardipine. Nevertheless, conditions were similar on day 1 both at week 0 and week 8 and we therefore feel that the conclusions concerning response to exercise and GTN are valid. A further factor which may have contributed to the difference is that measurements undertaken on day 2 were performed after a further 24 h period of bed rest, perhaps favourably affecting any apparent improvement in parameters after 8 weeks of therapy with nicardipine.
It is known that attenuation of the effect of vasodilatinnwith postural change or alternatively it may be due to a drugs after chronic dosage may occur [20] . In the present study responses after intravenous nicardipine produced similar end-values at week 0 and week 8, albeit that the magnitude of responses at week 8 was less. It is impossible to be certain whether the apparent improvement in control values after 8 weeks reflects a residual effect on the last oral dose of nicardipine or simply an improvement in the heart failure state. It is possible that the maximum vasodilator capacity after intravenous nicardipine had been reached at week 0 so that some of the apparent reduction in magnitude of effect may have been related to an inability of the drug to cause further vasodilatation. It is important to note that resting haemodynamic values at least 10 h after the last oral dose of the drug provided a poor guide to the overall clinical response and belied a marked difference in the haemodynamic response to exercise and GTN.
The main limitation of the present study is the lack of a placebo control group. Despite this, the magnitudc of the changes in treadmill capacity and bicycle haemodynamic responses suggest a real effect. In addition all patients underwent exercise training before the study in order to obtain a stable baseline exercise capacity. The difference in capacity between the two forms of exercise reflects the nature of the work undertaken. Although both were undertaken in the upright position, the treadmill provides a more dynamic form of exercise, less dependent on muscle strength and better simulates daily activity. Bicycle exercise incorporates an element of isometric exercise and is more dependent on leg muscle strength, which in practice was the limiting factor in this group of patients; nevertheless, haemodynamic measurements were facilitated using this form of exercise. A previous study has demonstrated that the symptom terminating exercise is dependent on the protocol adopted [21] . Using a fast protocol dyspnoea is more likely to terminate exercise than fatigue and its development may be related to the rate of production of metabolic acidosis rather than the rise in pulmonary capillary wedge pressure. In this study the treadmill protocol may be regarded as faster than the bicycle protocol and this may also have contributed to the differences in limiting symptoms.
The marked decrease in afterload development during exercise after 8 weeks of treatment was associated with an improvement in left ventricular function, the increased cardiac output being mainly due to the increase in stroke volume. The change in pulmonary pressures on exercise was little affected by the vasodilator, but the expected decrease may have been offset by an increased venous return due to muscle pumping. In any event, changes in pulmonary vascular responses are less evident on upright exercise than on supine exercise [22] and, in patients with chronic heart failure, there is no correlation between exercise capacity and pulmonary wedge pressure [2 11.
In conclusion, improvement in heart failure as evidenced by increased exercise capacity and improved exercise haemodynamic responses was observed with chronic arteriolar vasodilatation despite a lack of residual vasodilatation at rest. Secondary increased vasodilator responsiveness to other physiological and pharmacological stimuli is likely to have contributed to this beneficial clinical response. Haemodynamic parameters measured at rest appear to provide a poor guide to the clinical response after chronic vasodilator therapy.
